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Abstract: Objective: To examine whether painful physical symptoms (PPS) can be considered within the spectrum of de-
pressive symptoms. Methods: Data for this post-hoc analysis were taken from a 6-month observational study mostly con-
ducted in East Asia, Mexico, and the Middle East of 1,549 depressed patients without sexual dysfunction at baseline. Both 
explanatory and confirmatory factor analyses (EFA and CFA) were performed on the combined items of the 16-item 
Quick Inventory of Depressive Symptomatology Self-Report and the Somatic Symptom Inventory (seven pain-related 
items only). An additional second-order CFA was also conducted to examine an association between retained factors and 
the overall “depressive symptoms” factor. In addition, Spearman’s correlation was used to assess levels of correlation be-
tween retained factors and depression severity as well as quality of life. Results: Both EFA and CFA suggested and vali-
dated a four-factor solution, which included a pain factor. The other three factors identified were a mood/cognitive factor, 
a sleep disturbance factor, and an appetite/weight disturbance factor. All four factors were significantly associated with 
the overall factor of depression. They were also highly correlated to depression severity and quality of life (p<0.001 for 
all). The levels of correlations with the pain factor were generally greater than those with the appetite/weight factor and 
similar to those with the sleep factor. Conclusion: It may be reasonable to consider PPS within a broad spectrum of de-
pressive symptoms. At least, they should be routinely assessed in patients with depression. Further research is warranted 
to validate these preliminary findings.  
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INTRODUCTION 
Depression is one of the most prevalent, disabling and 
costly mental disorders, currently affecting nearly 350 mil-
lion people worldwide [1]. Many patients with depression 
often experience both psychological and somatic symptoms 
[2, 3]. Indeed, somatic manifestations of unipolar depression 
are frequently observed in both inpatient and outpatient care 
settings across all cultures [4], and that somatic symptoms 
are often the main reason for the initial visit to the primary 
care physician [5].  
The high prevalence of somatic symptoms in unipolar 
depression has been recognised and partially reflected in 
contemporary diagnostic criteria such as those specified in 
the Diagnostic and Statistical Manual of Mental Disorders-
editions [6, 7], which give an important emphasis to those 
somatic symptoms such as insomnia, weight loss, appetite 
change, fatigue, and psychomotor retardation [8]. Similarly, 
several somatic symptoms have also been included in 
widely-used depression rating scales such as the Hamilton 
Rating Scale for Depression (HRSD) [9], the Montgomery–
Åsberg Depression Rating Scale (MADRS) [10], the Beck  
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Depression Inventory (BDI) [11], and the Inventory of De-
pressive symptomatology (IDS) [12, 13]. 
A number of factor analytic studies on these rating scales 
in patients with unipolar depression have identified the so-
matic symptom components in the factor structure of the 
scales [14]. For instance,  Gullion and Rush [14] performed a 
factor analysis on the combined items of the IDS, the HRSD, 
and the BDI collected from 324 outpatients with major de-
pressive disorder (MDD), and identified the following ten 
primary factors: “hedonic capacity”, “self-blame”, “sui-
cide/hopelessness”, “lack of energy”, “sleep disturbance”, 
“decreased libido”, “somatic anxiety”, “anxious/irritable”, 
“sleep onset insomnia”, and “appetite disturbance/weight 
change”. Other factor analytic studies on single measures 
have identified fewer factors but still identified the somatic 
symptom component. With the HRSD-17 data from 186 pa-
tients with depression, Pancheri et al. identified the follow-
ing four factors: “somatic anxiety/somatisation” factor, a 
“psychic anxiety dimension”, a “pure depressive dimension”, 
and “anorexia” factor [15]. Similarly, another factor analysis, 
using the IDS-28 and IDS-30 data from 353 depressed out-
patients, found “cognitive/mood”, “anxiety/arousal”, and 
“sleep and appetite regulation” factors for each scale [12].  
Nevertheless, the question on which symptoms are spe-
cific to clinical depression still remains unanswered. That is, 
there are still disputes on the array of symptoms that consti-
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tutes the depressive syndrome and on the use of adequate 
symptom measures [14]. Different scales include different 
items, and consequently factor analytic studies of the rating 
scales have often produced different results in terms of factor 
numbers and contents [e.g., 12, 16-18]. The choice of the 
items may depend on the goal of a rating scale. The scale can 
be unidimensional if it aims to measure “general depression 
severity”, or multidimensional if it aims to identify and 
measure different subtypes having different symptom pro-
files.  
Painful physical symptoms (PPS) could potentially be 
considered another array of depressive symptoms, although 
the rating scales widely available rarely include these symp-
toms. Notably, PPS such as headaches, abdominal pain, 
heart/chest pain, and back pain are one of the most frequent 
complaints in patients with depression. These symptoms 
have been reported by up to 73% of outpatients with depres-
sion [5, 19-21]. Moreover, the majority of patients with de-
pression report multiple pain complaints and more pain 
symptoms have been associated with greater severity of de-
pression [22]. 
Given a strong link between pain and depression, our 
study aimed to understand whether PPS could be considered 
within the spectrum of depressive symptoms, using data 
from a 6-month, prospective, observational study with pa-
tients with MDD mostly from East Asia, Mexico and the 
Middle East. In doing so, both explanatory and confirmatory 
factor analyses were performed on the combined items of 
the16-item Quick Inventory of Depressive Symptomatology-
Self Report (QIDS-SR16) [23] and the Somatic Symptom 
Inventory (SSI) (pain-related items only) [24] to examine a 
factor structure of these items. 
METHODS 
Study Design  
Data for this post-hoc analysis were taken from a 6-
month, international, prospective, non-interventional, obser-
vational study, primarily designed to examine treatment-
emergent sexual dysfunction (TESD) and other treatment 
outcomes among patients with MDD who were treated with 
either a selective serotonin reuptake inhibitor (SSRI) or a 
serotonin-norepinephrine reuptake inhibitor (SNRI) in actual 
clinical practice. A total of 1,647 patients were enrolled at 88 
sites between 15 November 2007 and 28 November 2008. Of 
these, the 1,549 patients were classified as “sexually active 
patients without sexual dysfunction at study entry”, and in-
cluded in the study. The patients were drawn from the fol-
lowing countries and regions across the globe: East Asia 
(China [n=205; 13.2%], Hong Kong [n=18; 1.2%], Malaysia 
[n=33; 2.1%], the Philippines [n=113; 7.3%], Taiwan 
[n=199; 12.8%], Thailand [n=17; 1.1%], and Singapore 
[n=2; 0.1%]), the Middle East (Saudi Arabia [n=179; 11.6%] 
and United Arab Emirates [n=135; 8.7%]), Mexico (n=591; 
38.2%), and other regions (Israel [n=9; 0.6%] and Austria 
[n=48; 3.1%]). This study followed the ethical standards of 
responsible local committees and the regulations of the par-
ticipating countries, and was conducted in accordance with 
the ethical principles that have their origin in the Declaration 
of Helsinki and are consistent with Good Clinical Practice 
(GCP) where applicable to a study of this nature. Ethical 
Review Board (ERB) approval was obtained as required for 
observational studies wherever required by local law. All 
patients provided informed consent for the provision and 
collection of the data. Further details of the study design 
have been published elsewhere [25, 26].  
Study Population 
Patients (outpatients) were eligible to participate in the 
study if they met the following inclusion criteria: (1) pre-
sented with an episode of MDD within the normal course of 
care, with MDD diagnosed according to the International 
Statistical Classification of Diseases 10
th
 revision (ICD-10) 
[27] or Diagnostic and Statistical Manual of Mental Disor-
ders-4th edition text revision (DSM-IV-TR) [7] criteria; (2) 
were at least moderately depressed, defined by the Clinical 
Global Impression-Severity scale (CGI-S) (with a score of 
?4) [28]; (3) were initiating or switching to any available 
SSRI or SNRI antidepressant in accordance with each coun-
try’s approved labels and at the discretion of the participat-
ing psychiatrist; (4) at least 18 years of age; (5) sexually ac-
tive (with partner or autoerotic activity, including during the 
2 weeks prior to study entry) without sexual dysfunction, as 
defined by Arizona Sexual Experience Scale [29]; (6) not 
participating in another currently ongoing study; and (7) pro-
vided consent to release data. The study excluded the 
patients who had the following: (1) a history of treatment-
resistant depression (defined as failure to respond to treat-
ment with two different antidepressants from different 
classes at therapeutic doses for ?4 weeks); (2) a past or cur-
rent diagnosis of schizophrenia, schizophreniform or 
schizoaffective disorder, bipolar disorder, dysthymia, mental 
retardation or dementia; or (3) received any antidepressant 
within 1 week (1 month for fluoxetine) prior to study entry, 
with the exception of patients receiving an ineffective treat-
ment for whom the immediate switch to an SSRI or SNRI 
antidepressant was considered to be the best treatment op-
tion. Patients who changed or discontinued medication after 
entry remained in the study unless lost to follow-up or con-
sent was withdrawn. Treatment decisions were made solely 
at the discretion of the treating psychiatrist, and were inde-
pendent of study participation. Patients were not required to 
continue taking the medication initiated at baseline. Changes 
in medication and dosing as well as the use of concomitant 
medications and non-pharmacological therapies for the 
treatment of depression were possible at any time as deter-
mined by the treating psychiatrist. 
Data Collection and Outcome Assessment 
Data collection for the study occurred during visits 
within the normal course of care. The routine outpatient visit 
at which patients were enrolled served as the time for base-
line data collection. Subsequent data collection was targeted 
at 8, 16 and 24 weeks since the baseline visit. Patient demo-
graphics and clinical history were recorded at the baseline 
assessment.  
Depression and Pain Measures for Factor Analysis 
Clinical severity of depression was assessed at each visit 
using the QIDS-SR16 [23], which is a shorter version of the 
30-item Inventory of Depressive symptomatology [12, 13]. It 
132    Clinical Practice & Epidemiology in Mental Health, 2015, Volume 11 Hong et al. 
is a patient-rated, 16-item instrument designed to assess the 
severity of depressive symptoms in the past seven days. It 
covers the nine diagnostic symptom domains used to charac-
terise a major depressive episode, without items to assess 
atypical, melancholic or their commonly associated symp-
toms. It includes the following 16 items: (1) falling asleep 
(sleep onset insomnia); (2) sleep during the night (mid-
nocturnal insomnia); (3) waking up too early (early morning 
insomnia); (4) sleeping too much (hypersomnia); (5) feeling 
sad; (6) decreased appetite or (7) increased appetite; (8) de-
creased weight (within the last two weeks) or (9) increased 
weight (within the last two weeks): (10) poor concentra-
tion/decision-making; (11) view of myself (self-criticism or 
blame); (12) suicidal thoughts; (13) low level of general in-
terest; (14) low level of energy; (15) feeling slowed down 
(psychomotor retardation); and (16) feeling restless (psy-
chomotor agitation). Item responses are ranked from 0 to 3, 
with higher scores corresponding with more frequent symp-
toms/problems. In the current factor analysis, items 6 and 7 
(increased and decreased appetite) and items 8 and 9 (in-
creased and decreased weight) were combined into single 
items respectively (i.e., appetite disturbance for the former 
and weight change for the latter) because patients were re-
quired to complete only one of each.  
Depression-related pain severity was measured using the 
seven pain-related items of the 28-item modified SSI (mus-
cle soreness, abdominal pain, lower back pain, heart/chest 
pain, joints pain, neck pain, and headaches) [21, 24]. It is a 
patient self-report scale that assesses the extent to which 
each of 28 somatic symptoms has bothered the patient over 
the previous week, using a scale ranging from 1 (“not at all”) 
to 5 (“a great deal”) [24]. Of the 28 somatic symptoms, only 
the seven pain-related items were administered to the pa-
tients and were, therefore, included in this factor analysis. 
Other Outcome Measures 
Overall clinical severity was assessed at each visit by 
treating psychiatrists using the CGI-S [28]. It is rated on a 7-
point scale, ranging from 1 (normal, not at all ill) to 7 (ex-
tremely ill). 
Patient perception of quality of life was also assessed us-
ing the EuroQoL-5 Dimensions (EQ-5D). This instrument 
has five items (mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression), each of which is 
scored on a scale from 1 (no problems) to 3 (extreme prob-
lems). Given that there are no single representative EQ-5D 
tariffs or country-specific tariffs for all countries included in 
this study, the commonly used UK tariff was applied to the 
EQ-5D data to calculate the utility score [30]. The EQ-5D 
questionnaire also includes a visual analogue scale (EQ-
VAS) on which patients were asked to rate their current 
overall health that day on a scale from 0 (worst imaginable 
health state) to 100 (best imaginable health state), thus pro-
viding an overall ‘health state’ score. 
Statistical Analysis 
The current study included a total of 1,332 patients who 
initiated either duloxetine or an SSRI as monotherapy at 
baseline for the treatment of MDD, and who did not have 
missing data on the QIDS-SR16 score at baseline with at least 
one assessable QIDS-SR16 score during follow-up.  
The sample was randomly divided into two subsamples 
for explanatory factor analysis (EFA) and subsequent con-
firmatory factor analysis (CFA) to identify and validate a 
factor structure of the combined QIDS-SR16 and SSI-pain 
related items. The baseline patient characteristics between 
the two subsamples were compared and tested using the Chi-
square test (for categorical variables) and t-tests (for con-
tinuous variables).  
EFA on the ordinal responses of the QIDS-SR16 and the 
SSI-pain related items collected at baseline was first carried 
out with the first half of the sample to extract a factor solu-
tion, using a polychoric correlation matrix and the mean- and 
variance-adjusted weighted least square (WLSMV) esti-
mates. A genomic rotation, which is an oblique type of rota-
tion that allows the factors to correlate, was also used.  
 The best factor solution was determined based on Kai-
ser’s criterion (eigenvalues above 1), inspection of the 
screeplot, and the fit indices such as the Root Mean Square 
Error of Approximation (RMSEA), the Comparative Fix 
Index (CFI), the Tucker-Lewis Index (TLI), and the Stan-
dardised Root Mean Square (SRMR). The following values 
indicate the cut-off for a good model fit: the RMSEA value 
of <0.06, the CFI value of >0.90 (preferably 0.95), the TLI 
value of >0.95, and the SRMR value of <0.08 [31]. In addi-
tion, factor loadings after rotation were examined to load the 
items onto a particular factor, based on factor loadings (i.e. a 
loading [absolute value] of at least 0.3) and clinical judge-
ment.  
CFA was then applied to the second half of the sample to 
evaluate the model derived through EFA on the first half-
sample. It was performed on the ordinal responses of the 
QIDS-SR16 and the SSI-pain items collected at baseline but 
also at each post-baseline visit. Given that we combined the 
items of two measures (i.e. QIDS-SR16 and SSI pain-related 
items), a second-order factor analysis (i.e. adding an overall 
factor of “depressive symptoms” to the best factor solution 
identified in EFA) was also conducted to examine the rela-
tionship of each factor (i.e., first-order factor) with an overall 
factor (i.e. second-order factor). The fit of the models was 
assessed using the following fit indices: RMSEA, CFI, and 
TLI.  
In addition, the levels of correlation between each factor 
and outcome measures (i.e., clinical severity [CGI-S and 
QIDS-SR16 scores] and quality of life [EQ-5D and EQ-VAS 
scores]) at each visit were also examined using Spearman’s 
correlation to check the relevance of each factor in explain-
ing the outcome measures. The scores of each factor were 
computed as the sum of the items that formed the factor.  
Descriptive statistics were obtained using SAS version 
9.3 software for Windows (SAS Institute, Cary, NC, USA), 
and all factor analyses were performed using Mplus version 
7.2 software (Muthén & Muthén, Los Angeles, CA, USA).  
RESULTS 
Patient Characteristics at Study Entry 
Table 1 describes the demographic and clinical character-
istics of the 1,332 patients at baseline. The mean age 
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Table 1.  Baseline patient characteristics. 
Baseline Characteristic 
Subset 1 
(n=666) 
Subset 2 
(n=666) 
Total 
(n=1,332) 
Age, mean (SD) 37.8 (10.5) 38.2 (10.5) 38.0 (10.5) 
Female, % 56.6 56.3 56.5 
Region, %    
    East Asia 34.5 33.8 34.2 
    Mexico 40.8 43.5 42.2 
    The Middle East 22.5 19.7 21.1 
    Other region 2.1 3.0 2.6 
Age at first symptoms of MDD, mean (SD) 33.6 (11.3) 33.8 (11.1) 33.7 (11.2) 
BMI (kg/m2), mean (SD) 24.8 (4.3) 24.6 (4.3) 24.7 (4.3) 
Living with a spouse/partner, % 65.9 64.6 65.2 
Educational attainment, %    
    ? Primary school 7.4 9.2 8.3 
    Secondary school/occupational programme 44.7 43.3 44.0 
    ? University 47.9 47.6 47.8 
Employment status, %    
    Full-time 55.9 55.3 55.6 
    Economically inactive 27.0 25.1 26.1 
    Unemployed/part-time 17.1 19.7 18.4 
    CGI-S score at baseline, mean (SD) 4.5 (0.7) 4.5 (0.7) 4.5 (0.7) 
    QIDS-SR16 score at baseline, mean (SD) 14.2 (4.9) 14.5 (4.8) 14.4 (4.8) 
    EQ-VAS score at baseline, mean (SD) 43.6 (26.1) 42.7 (25.7) 43.2 (25.9) 
    EQ-5D index at baseline, mean (SD) 0.48 (0.33) 0.46 (0.33) 0.47 (0.33) 
    SSI-pain score at baseline, mean (SD) 14.5 (5.1) 14.3 (5.1) 14.4 (5.1) 
    Had MDD episodes in the 24 months prior to baseline, % 65.8 65.6 65.7 
    Had been hospitalised for MDD in the 24 months prior to baseline, % 5.3 5.4 5.3 
    Initiating treatment with SSRIs (vs. duloxetine), % 58.9 57.7 58.3 
    Having significant co-morbidities, % 24.3 26.8 25.6 
Painful physical symptoms, % 53.0 49.9 51.5 
Abbreviations: BMI, Body Mass Index; CGI-S, Clinical Global Impressions of Severity; EQ-VAS, EuroQoL-Visual Analogue Scale; EQ-5D, EuroQoL-5 Dimensions; MDD, Major 
Depressive Disorder; QIDS-SR16, 16-item Quick Inventory of Depressive Symptomatology Self-Report; SD, Standard Deviation; SSI-pain, Somatic Symptom Inventory; SSRI, 
Selective Serotonin Reuptake Inhibitor 
 
(standard deviation [SD]) of the patients was 38.0 years 
(SD=10.5) and 56.5% were female. More than one in three 
were from Mexico (42.2%), followed by East Asia (34.2%), 
the Middle East (21.1%) and other regions (i.e., Israel and 
Austria, 2.6%). Approximately two-thirds of the patients 
(65.7%) had experienced a depressive episode in the 24 
months prior to baseline. In addition, about one in four 
(25.6%) had at least one comorbidity at baseline, and about 
half of the patients (51.5%) had painful physical symptoms 
(defined as a mean score of ?2 for the SSI pain-related items 
[21]). A total of 556 patients (41.7%) initiated duloxetine 
and the rest (58.3%) initiated an SSRI at baseline. Depres-
sion severity at baseline was moderate to severe, as demon-
strated by the CGI-S score (mean=4.5, SD=0.7) and the 
QIDS-SR16 score (mean=14.4, SD=4.8). The level of quality 
of life was relatively lower, as demonstrated by the EQ-5D 
score (mean=0.47, SD=0.33) and EQ-VAS score 
(mean=43.2, SD=25.9).  
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This patient sample was randomly split into two groups: 
sample 1 for EFA and sample 2 for CFA. They were virtu-
ally identical with no statistically significant differences on 
any measures/variables collected.  
Results of EFA and CFA 
The explanatory factor analysis on a total of 21 items 
from the QIDS-SR16 (14 items) and the SSI (7 pain-related 
items) was first performed with the first half of the sample. 
The scree plot, presented in Fig. (1), demonstrates the eigen-
values of each additional factor (i.e., the variance that is ac-
counted for by that factor). The eigenvalues dropped below 1 
and reached a “plateau” at the 5th factor (1.431 for the 4th 
factor and 0.928 for the 5th factor), suggesting a four-factor 
solution. The following fit indices also confirmed a good fit 
of the four factor model: RMSEA=0.041; CFI=0.979; 
TLI=0.967; and SRMR=0.029.  
 
 
Fig. (1). A scree plot for the eigenvalues of unrotated factors. 
 
Table 2 presents the item loadings on each factor after 
the geomin rotation. The items assigned to each relevant 
factor, based on factor loadings (i.e. a loading [absolute 
value] of at least 0.3) and clinical judgement, are highlighted 
in bold in Table 2. Each factor was composed of two to nine 
items. The first factor (factor I), “mood/cognitive factor”, 
consisted of nine items: hypersomnia; feeling sad; concentra-
tion/decision-making; self-criticism and blame; suicidal 
thoughts; interest in people/activities; energy/fatigability; 
psychomotor retardation; and psychomotor agitation. The 
second factor (factor II), “sleep disturbance”, was composed 
of four items: sleep onset insomnia; mid-nocturnal insomnia; 
early morning insomnia; and hypersomnia. The third factor 
(factor III), “appetite/weight disturbance”, consisted of two 
items: appetite disturbance and weight change. Finally, fac-
tor IV, “pain”, consisted of seven items: muscle soreness; 
abdominal pain; lower back pain; check/heart pain; joint 
pain; neck pain; and headache. The two items, suicidal 
thoughts (0.26) and psychomotor agitation (0.29), were 
loaded onto the first “mood” factor according to clinical 
judgement, although their factor loadings were slightly be-
low 0.3. Similarly, the item, suicidal thoughts (0.34), was not 
loaded onto the third “appetite/weight disturbance” factor. 
Notably, factor I to factor III were all composed of the items 
of the QIDS-SR16, and factor IV was all composed of the SSI 
pain-related items.  
The confirmatory factor analysis was then performed 
with the second half of the sample to test the fit of this four-
factor solution. Fit indices indicated a reasonably good fit of 
the four factor model: RMSEA=0.054; CFI=0.954; and 
TLI=0.947. All items also exhibited a factor loading (abso-
lute value) of at least 0.3 (see Table 3). In addition, the 
oblique type of rotation among the four factors obtained a 
factor inter-correlation matrix, in which all four factors were 
significantly correlated with one another, ranging from 0.26 
(mood/cognitive with pain) to 0.54 (mood/cognitive with 
sleep disturbance).  
A second-order CFA with the four-factor solution was 
also performed to examine the relationship of each factor 
(first-order factors) with an overall second-order factor of 
“depressive symptoms”. Again, fit indices indicated a rea-
sonably good fit: RMSEA=0.054; CFI=0.953; and 
TLI=0.946. Notably, these analyses were repeated with the 
data collected at each visit, and all confirmed a good fit of 
the four-factor solution, regardless of the addition of the sec-
ond-order factor.  
Fig. (2) graphically presents the relationship between the 
first-order factors (i.e., mood/cognitive, sleep disturbance, 
appetite/weight disturbance, and pain) and the second-order 
factor. The loadings of the first-order factors on the second-
order factor indicated that each specific factor was signifi-
cantly associated with the overall second-order factor. Al-
though the pain factor was most weakly associated with the 
overall factor, the association appeared to be still significant 
and important with a loading of 0.43. The other first-order 
factors exhibited stronger associations with the overall factor 
(factor loadings: 0.78 for sleep disturbance, 0.68 for mood, 
and 0.60 for appetite/weight disturbance). Notably, their 
squared values, which indicate a proportion of the variance 
in each factor explained by the second-order factor, ranged 
from 18.1% (pain) to 61.3% (sleep disturbance).  
Correlation between Factors and Outcomes 
Table 4 shows the levels of correlation between the score 
of each factor (i.e., mood/cognitive, sleep disturbance, appe-
tite/weight disturbance, and pain) and the score of each out-
come measure (symptom severity [i.e. CGI-S and QIDS-
SR16 scores] and quality of life [EQ-5D and EQ-VAS 
scores]) both at baseline and at 24 weeks. All factors includ-
ing the pain factor were positively correlated to depression 
severity and negatively correlated to the level of quality of 
life both at baseline and at 24 weeks (p<0.001 for all correla-
tions).  
The mood/cognitive factor was most strongly correlated 
to all types of outcomes measured both at baseline and at 24 
weeks, followed by the sleep disturbance factor. In general, 
all factors exhibited stronger correlations at 24 weeks than at 
baseline, especially pain and sleep disturbance. At 24 weeks, 
the level of correlation with the pain factor was generally 
greater than that with the appetite/weight disturbance factor, 
and similar to that with the sleep disturbance factor. For ex-
ample, the mood factor was still most strongly correlated to 
EQ-5D scores with a correlation coefficient of -0.654, fol-
lowed by pain (-0.557), sleep disturbance (-0.484), and 
0
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Table 2.  Pattern of factors after rotation in explanatory factor analysis using the baseline data. 
Factors 
Items (QIDS-SR16 and SSI pain-related items) 
Factor I Factor II Factor III Factor IV 
1. Sleep onset insomnia 0.04 0.72 0.10 -0.01 
2. Mid-nocturnal insomnia -0.01 0.72 0.004 0.08 
3. Early morning awakening 0.06 0.67 -0.14 0.03 
4. Hypersomnia 0.38 -0.34 -0.20 0.07 
5. Feeling sad 0.68 -0.01 0.13 -0.01 
6+7. Appetite disturbance 0.17 0.01 0.71 0.000 
8+9. Weight disturbance 0.04 -0.02 0.77 0.06 
10. Concentration/decision-making 0.74 0.06 0.01 -0.03 
11. Self-criticism and blame 0.49 0.03 0.17 0.02 
12. Suicidal thoughts 0.26 0.09 0.34 0.07 
13. Interest in people/activities 0.69 -0.01 0.12 -0.04 
14. Energy/fatigability 0.76 0.03 0.04 0.004 
15. Psychomotor retardation 0.61 0.12 -0.08 0.07 
16. Psychomotor agitation 0.29† 0.19 0.07 0.01 
17. Muscle soreness 0.03 0.01 -0.05 0.80 
18. Abdominal pain -0.21 0.02 0.20 0.64 
19. Lower back pain 0.09 -0.06 0.02 0.70 
20. Heart/chest pain -0.05 0.06 0.23 0.54 
21. Joints pain -0.06 0.03 0.01 0.74 
22. Neck pain 0.23 -0.11 0.01 0.70 
23. Headache 0.15 0.08 -0.11 0.55 
Interpretation 
Mood/ 
cognitive 
Sleep disturbance 
Appetite/ 
weight disturbance 
Pain 
Note 1: Bolded items indicate major loadings for each item, which were finally loaded onto the factors based on their loading values (i.e., an absolute value of >0.3) and clinical 
judgement.  
Note 2: Item 1-16 are the items included in the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16), and Item 17-23 are the seven pain-related items of 
the Somatic Symptom Inventory (SSI). Factor analysis was performed with a total of 21 items (item 6 and 7 as well as item 8 and 9 were combined into one item, respectively).  
 
appetite/weight disturbance (-0.264). Notably, the pain factor 
was also significantly correlated to both CGI-S scores and 
QIDS-SR16 scores with correlation coefficients of 0.559 and 
0.411, respectively.  
DISCUSSION 
This paper describes a preliminary investigation into 
whether painful physical symptoms could be considered 
within the spectrum of depressive symptoms, using a factor 
analysis on the combined items of the QIDS-SR16 and the 
SSI (pain-related items only). Both explanatory and confir-
matory factor analyses suggested and validated a four-factor 
solution and that this factor structure included a factor that 
solely consisted of pain-related items (i.e. a pain factor). The 
other three factors identified were labelled (1) a 
mood/cognitive factor, (2) a sleep disturbance factor, and (3) 
an appetite/weight disturbance factor, respectively, according 
to the nature of the symptoms (i.e. items) included in each 
factor. The relevance of painful physical symptoms was also 
supported by the second-order factor analysis, showing an 
important and significant relationship between the pain fac-
tor and the overall factor of “depressive symptoms”. In addi-
tion, this pain factor was significantly correlated to depres-
sion severity and quality of life.  
Painful Physical Symptoms within the Spectrum of De-
pressive Symptoms 
The importance of somatic symptoms in depression has 
been well established in the literature, and partially reflected 
in diagnostic classification systems and rating scales for de-
pression. However, painful physical symptoms have been 
rarely included in such rating scales, although they are one 
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Table 3.  Standardised factor loadings in confirmatory factor analysis using the baseline data. 
Factors  
Items (QIDS-SR16 and SSI pain-related items) 
Mood/ 
cognitive 
Sleep  
disturbance 
Appetite/ 
Weight disturbance 
Pain R
2
 
1. Sleep onset insomnia  0.74   0.55 
2. Mid-nocturnal insomnia  0.78   0.61 
3. Early morning awakening  0.67   0.44 
4. Hypersomnia 0.38 -0.36   0.14 
5. Feeling sad 0.65    0.43 
6+7. Appetite disturbance   0.97  0.94 
8+9. Weight disturbance   0.64  0.41 
10. Concentration/decision-making 0.76    0.57 
11. Self-criticism and blame 0.58    0.33 
12. Suicidal thoughts 0.52    0.27 
13. Interest in people/activities 0.77    0.59 
14. Energy/fatigability 0.74    0.55 
15. Psychomotor retardation 0.74    0.54 
16. Psychomotor agitation 0.51    0.26 
17. Muscle soreness    0.76 0.58 
18. Abdominal pain    0.63 0.39 
19. Lower back pain    0.78 0.60 
20. Heart/chest pain    0.62 0.38 
21. Joints pain    0.76 0.58 
22. Neck pain    0.77 0.59 
23. Headache    0.68 0.47 
Note 1: R2 is the proportion of the item variance that is explained by the factor.  
Note 2: Item 1-16 are the items included in the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16), and Item 17-23 are the seven pain-related items of 
the Somatic Symptom Inventory (SSI). Factor analysis was performed with a total of 21 items (item 6 and 7 as well as item 8 and 9 were combined into one item, respectively).  
 
 
Fig. (2). Standardised factor loadings in confirmatory factor analysis with a second-order factor model using the baseline data. 
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Table 4.  Level of correlations between the four factors retained and outcomes of depression (symptom severity and quality of life). 
Outcomes 
Mood/ 
cognitive 
Sleep disturbance 
Appetite/ 
Weight disturbance 
Pain 
At baseline     
QIDS-SR16 0.958 0.552 0.530 0.286 
CGI-S 0.427 0.223 0.106 0.104 
EQ-VAS -0.296 -0.134 -0.201 -0.176 
EQ-5D -0.481 -0.215 -0.244 -0.344 
At 24 weeks     
QIDS-SR16 0.919 0.744 0.547 0.559 
CGI-S 0.735 0.491 0.214 0.411 
EQ-VAS -0.436 -0.324 -0.170 -0.308 
EQ-5D -0.654 -0.484 -0.264 -0.557 
Note: p-value <0.001 for all correlations 
Abbreviations: CGI-S, Clinical Global Impressions of Severity; EQ-VAS, EuroQoL-Visual Analogue Scale; EQ-5D, EuroQoL-5 Dimensions; QIDS-SR16, 16-item Quick Inventory 
of Depressive Symptomatology Self-Report 
 
of the most frequent complaints in patients with depression 
[20, 32], and are known to be associated with an unfavour-
able course of depression [33-35]. 
Notably, there has long been a concern over the inclusion 
of somatic symptoms, painful physical symptoms in particu-
lar, in the rating scales or in the diagnostic classification sys-
tem. This is because patients with medical conditions can 
also report somatic symptoms for reasons other than depres-
sion, and therefore, the inclusion of these symptoms could 
lead to the overestimation of depression prevalence rates, 
that is, a high level of false positive diagnoses  
Indeed, the exact mechanism behind the link between de-
pression and pain has not been fully understood yet. For ex-
ample, we do not know whether a causal relationship exists 
between the two and, if it exists, which condition is the 
cause. What we know or believe is that both conditions share 
a common biological pathway and an imbalance of serotonin 
and norepinephrine is likely involved in the pathophysiology 
of both conditions [32]. It is, therefore, reasonable to suspect 
the involvement of transmitter dysregulation, thereby a diag-
nosis of depression, when painful symptoms are not ex-
plained by organic pathologies. Given that psychiatric disor-
ders are generally diagnosed solely based on symptom pro-
files, it is particularly important to identify a full spectrum of 
depressive symptoms, which will certainly help to better 
individualise treatment for patients with depression. In this 
light, our factor analytic findings suggest that painful physi-
cal symptoms could be considered another array of depres-
sive symptoms, reinforcing the need for routine PPS assess-
ment in patients with depression, especially given the high 
level of correlation between such symptoms and depression 
severity as well as quality of life. In addition, it may be rea-
sonable to include painful physical symptoms in rating scales 
for depression, at least a subscale, although it requires a care-
ful caution to avoid false positive diagnoses.  
Fornaro et al. (2011): The fact that medically unex-
plained somatic complaints were essentially not associated 
with biopolarity is also a remarkable result since it was ini-
tially expected to be related to the “excitement” of mania. 
Rather, the total number of somatic symptoms (including 
both painful and non-painful somatic symptoms) was higher 
among those with a bipolar diagnosis. Painful physical 
symptoms could be less represented in “bipolar” MDEs than 
unipolar MDEs.  
Other Factors: Mood/Cognitive, Sleep Disturbance, and 
Appetite/Weight Disturbance 
The other three factors identified (i.e., mood/cognitive, 
sleep disturbance, and appetite/weight disturbance) were all 
internally consistent, appeared clinically plausible, and were 
largely similar to those identified in previous research.  
Most factor analytic studies with patients with depression 
have proposed three to four factor models, regardless of a 
type of rating scale used, although there are some discrepan-
cies in the type and number of items loaded onto the factors 
across the studies. For example, Rush et al. extracted a cog-
nitive/mood factor, an anxiety/arousal factor, and a vegeta-
tive factor from each of the 30-item versions of IDS, Clini-
cian-Reported (IDS-C30) and Self-Report (IDS-SR30) [12]. 
Craighead and Evans proposed a four-factor solution that 
consisted of cognitive-pessimism, affective, cognitive-
anxiety, and vegetative factors, using the MADRS [17]. 
Similarly, Pancheri et al. also proposed a four-factor model 
that comprised a pure depressive dimension, a psychic anxi-
ety dimension, somatic anxiety/somatisation, and an ano-
rexia factor, using the HRSD-17 [15]. With the Zung self-
rated depression scale, Romera et al. also identified a core 
depressive factor, a cognitive factor, an anxiety factor, and a 
somatic factor [18].  
Despite the use of different labels, these studies have all 
identified a mood/cognitive factor, as in our study. This fac-
tor was composed of nine items in our study, including feel-
ing sad, poor concentration/decision-making, self-criticism 
and blame, suicidal thoughts, lack of interest in peo-
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ple/activities, energy/fatigability, psychomotor retardation, 
and psychomotor agitation. Similar items were also included 
in the mood/cognitive factor identified from the IDS-C30 and 
IDS-SR30 [12], which have greater content coverage, com-
pared to its shorter version, the QIDS-SR16, used in our 
study. However, the items, appetite disturbance and weight 
change, were included this mood/cognitive factor in the 
analysis with the IDS-SR30, while they were included in an-
other factor in our study as well as in the analysis with the 
IDS-C30. Consequently, the items included in the other two 
factors identified in our study (i.e., sleep disturbance and 
appetite/weight disturbance) were also more consistent with 
those included in the other two factors (i.e., anxiety/arousal 
and vegetative) of the IDS-C30 factor structure. Specifically, 
the anxiety/arousal factor included insomnia-related items 
(i.e., initial insomnia and middle insomnia), as in our study 
(for the sleep disturbance factor), as well as anxiety-related 
items, most of which were excluded in the QIDS-SR16. Simi-
larly, the vegetative factor included appetite disturbance and 
weight change, as in our study (for the appetite/weight dis-
turbance factor), with some sleep problems (e.g., sleeping 
too much and early morning awakening).  
However, it may not be surprising to observe some dis-
crepancies in the results of factor analytic studies because the 
profile of depressive symptoms is also likely to differ across 
different populations [36, 37]. Notably, our sample is geo-
graphically diverse, but mostly from the non-Western world 
(East Asia, Mexico, and the Middle East). Further research is 
required to validate our findings in different populations and 
regions.  
LIMITATION 
Our results should need to be interpreted in the context of 
the following study limitations. First, given that painful 
physical symptoms are rarely included in widely used rating 
scales for depression, we combined two different meas-
ures—the QIDS-SR16 and the SSI—to extract a factor struc-
ture of the combined items and to confirm whether pain con-
stitutes the factor structure as an independent factor. Al-
though we successfully identified the pain factor, it was 
solely composed of the seven pain-related items of the SSI. 
Thus, we cannot exclude the possibility that the identifica-
tion of the pain factor could be a statistical artefact, driven 
by a series of pain-related items taken from a different meas-
ure. Nevertheless, the Spearman’s correlation confirmed 
significant associations between the pain factor and depres-
sion severity, as well as quality of life. The correlation levels 
were generally greater than those with the appetite/weight 
disturbance factor and similar to those with the sleep distur-
bance factor at follow-up visits. Although these findings 
certainly indicate that painful physical symptoms have im-
plications for treatment outcomes, further research is still 
warranted to confirm the validity of the pain factor. Second, 
our study sample was taken from a psychiatric care setting of 
patients who had been diagnosed with major depression. 
Many primary care patients presenting with painful physical 
complaints have not received a diagnosis of depression; 
therefore, our results could have been different if we had 
included primary care patients with unexplained painful 
physical symptoms. Third, our study included patients from 
different regions of the world. It has been speculated that 
culture and ethnicity may influence somatic and psychiatric 
presentation of depression [38, 39]. We, however, did not 
conduct subgroup analyses by region because our sample 
was already divided into two subsamples; one for explora-
tory factor analysis and another for confirmatory factor 
analysis. Further research needs to test the validity of the 
pain factor in different cultures and ethnicities. Fourth, be-
cause the primary objective of this observational study was 
to assess the frequency of TESD in the treatment of MDD, 
the study included only those patients who were sexually 
active without sexual dysfunction at baseline. Sexual dys-
function has been reported to be two to three times more 
prevalent in patients with depression compared with the gen-
eral population [40, 41], and thus our findings may not be 
immediately generalizable to patients with MDD as a whole. 
Finally, because there are no single representative EQ-5D 
tariffs or country-specific tariffs for all countries included, 
we applied the commonly used UK tariff to the EQ-5D data 
to calculate utility scores [30].  
CONCLUSION 
This study represents one of the first attempts to explic-
itly evaluate the relevance of painful physical symptoms in 
defining a broader spectrum of depressive symptoms, with a 
sample of patients treated for MDD in psychiatric care set-
tings in the non-Western world. A factor analysis on the 
combined items of the QIDS-SR16 and the SSI (pain-related 
items) identified a pain factor in addition to a 
mood/cognitive factor, a sleep disturbance factor, and an 
appetite/weight disturbance factor. This pain factor was also 
significantly associated with the second-order factor of the 
overall depressive symptoms and highly correlated to de-
pression severity and quality of life at each follow-up visit. 
These findings generally suggest that painful physical symp-
toms should be routinely assessed in patients with depression 
and may need to be included in rating scales, at least as a 
subscale. Nevertheless, this is only a preliminary investiga-
tion, and further factor analytic studies, preferably with more 
comprehensive data from one single measure, are warranted 
to strengthen the basis of the present findings.  
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